Cargando…
Non-small cell lung cancer and CHART (continuous hyperfractionated accelerated radiotherapy)--where do we stand?
This paper reviews the use of hyperfractionated and/or accelerated radiation therapy in the curative treatment of non-small cell lung cancer, and explains the scientific rationale behind the development of these regimes. The indications, practicalities and economics of introducing them routinely are...
Autores principales: | Eakin, R. L., Saunders, M. I. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ulster Medical Society
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2449197/ https://www.ncbi.nlm.nih.gov/pubmed/11196724 |
Ejemplares similares
-
Continuous, hyperfractionated, accelerated radiotherapy (CHART).
por: Dische, S., et al.
Publicado: (1989) -
Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
por: Ataman, Ö U, et al.
Publicado: (2001) -
Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
por: Saunders, M. I., et al.
Publicado: (1998) -
Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985) -
Where Do We Stand?
Publicado: (1891)